In summary, the intranasal administration of the KYCCSRK peptide promoted an improvement in terms of AD pathology by reducing the amyloidogenic cleavage of APP as well as TAU phosphorylation likely mediated by reducing the expression levels of BACE1 and DYRK1A proteins. Here, APP is linked to Alzheimer disease.